Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a leader in the development of next-generation mental health treatments, has announced that its CEO, Doug Drysdale, will engage in a fireside chat at the upcoming Canaccord Genuity 45th Annual Growth Conference. Scheduled for August 12, 2025, in Boston, this event will spotlight Cybin's pioneering work in the neuropsychiatry sector, particularly its efforts to address the significant unmet needs in mental health care through innovative psychedelic-based therapies.
The live webcast of the fireside chat, set for 2:30 p.m. ET, will be accessible to a global audience, with an archived version available on Cybin's investor relations site. This participation underscores Cybin's commitment to advancing mental health treatments and its role as a key player in the psychedelic and cannabis industries. The company's focus on developing intermittent treatments that offer long-lasting results represents a potential paradigm shift in how mental health conditions are treated.
Cybin's current pipeline includes CYB003, a proprietary deuterated psilocin analog in Phase 3 studies for adjunctive treatment of major depressive disorder, and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. These investigational compounds highlight Cybin's innovative approach to mental health care, targeting 5-HT-receptor focused treatments that could offer new hope for patients worldwide.
Founded in 2019, Cybin has rapidly expanded its operations across Canada, the United States, the United Kingdom, the Netherlands, and Ireland. The company's dedication to revolutionizing mental healthcare is evident in its robust research pipeline and its active engagement with the scientific and investment communities. For those interested in learning more about Cybin's groundbreaking work, additional information can be found on their official website https://www.cybin.com.
The implications of Cybin's participation in the Canaccord Genuity conference are significant, not only for the company but for the broader mental health and psychedelic industries. By showcasing its latest developments and engaging with investors and stakeholders, Cybin is paving the way for the acceptance and integration of psychedelic-based therapies into mainstream medicine. This event represents a critical opportunity for Cybin to highlight the potential of its treatments to transform mental healthcare and improve the lives of millions suffering from mental health conditions.
